Portal de investigação
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Roque, K
- Ruiz, R
- Mas, L
- Vancini, M
- Silva, JA Jr
- de Mello, RA
Unidades de investigação
Abstract
Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung cancer patients without an oncogenic driver mutation. This comprehensive review provides an overview of immunotherapy treatment options and offers an algorithm for selecting the most appropriate regimen in various clinical scenarios. Additionally, we delve into practical considerations commonly encountered in clinical settings, as well as the latest advancements in the field.Abstract The introduction of immunotherapy has brought about a paradigm shift in the management of advanced non-small cell lung cancer (NSCLC). It has not only significantly improved the prognosis of patients but has also become a cornerstone of treatment, particularly in those without oncogenic driver mutations. Immune checkpoint inhibitors (ICIs) play a crucial role in the treatment of lung cancer and can be classified into two main groups: Anti-cytotoxic T lymphocyte antigen-4 (Anti-CTLA-4) and anti-T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti-PD-L1). Certainly, the landscape of approved first line immunotherapeutic approaches has expanded to encompass monotherapy, immunotherapy-exclusive protocols, and combinations with chemotherapy. The complexity of decision-making in this realm arises due to the absence of direct prospective comparisons. However, a thorough analysis of the long-term efficacy and safety data derived from pivotal clinical trials can offer valuable insights into optimizing treatment for different patient subsets. Moreover, ongoing research is investigating emerging biomarkers and innovative therapeutic strategies that could potentially refine the current treatment approach even further. In this comprehensive review, our aim is to highlight the latest advances in immunotherapy for advanced NSCLC, including the mechanisms of action, efficacy, safety profiles, and clinical significance of ICI.
Dados da publicação
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Review
- Páginas:
- 4547-
- Link para outro recurso:
- www.scopus.com
Cancers Multidisciplinary Digital Publishing Institute (MDPI)
Citações Recebidas na Scopus: 8
Documentos
- Não há documentos
Filiações
Keywords
- immune checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC); PD-1; PD-L1; CTLA-4; oncogenic driver mutation; treatment sequencing; tumour biomarkers; personalized medicine
Financiamento
Proyectos asociados
Resultados de um Protocolo QST em voluntários saudáveis e em pacientes com dor crónica: um ensaio clínico controlado
Investigador Principal: Daniel Humberto Pozza
Ensaio Clínico Académico (Dor Crónica) . 2023
Citar a publicação
Roque K,Ruiz R,Mas L,Pozza D,Vancini M,Silva JJR,de Mello RA. Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices. Cancers. 2023. 15(18):p. 4547-4547. IF:5,200. (2).
